The article identifies promising survival results in relapsed/refractory AML patients

warranting further study

Bergen, Norway - 26 March 2025 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the publication of a peer-reviewed article entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the journal Nature Communications.

This article is accessible here: www.nature.com/articles/s41467-025-58179-6.pdf

The article highlights results in 36 patients treated with a combination of BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low-dose cytarabine (LDAC) chemotherapy. Overall, patients who received the combination had an overall survival of 7.8 months, substantially longer than that expected in this difficult-to-treat patient population.

The lead investigator of the study, Professor Sonja Loges, MD, PhD. of the German Cancer Research Center (DKFZ), Heidelberg, Germany stated, "Following first line treatment of AML, most patients will relapse​​, and beyond first line the prognosis of older patients with relapsed or refractory AML, the population studied in BGBC003 is particularly poor. With other treatment approaches, the current overall survival of R/R AML patients is believed to be approximately 2.9-4 months.  The authors of this article believe that the BGBC003 results in this population warrant further study."

Olav Hellebo, CEO of BerGenBio commented "Our BGBC003 study evaluated bemcentinib in relapsed/refractory (R/R) AML patients who have limited effective treatment options today.  The presence of AXL is a poor prognostic factor in this population and AXL is believed to promote chemotherapy resistance and decreased antitumor immune response.  We believe, as a highly selective AXL inhibitor, bemcentinib holds promise as a treatment for these patients with extremely high unmet medical needs."

Contacts   

Olav Hellebo, BerGenBio ASA   

ir@bergenbio.com  

Rune Skeie, CFO, BerGenBio ASA   

rune.skeie@bergenbio.com  

Investor Relations / Media Relations   

Jan Lilleby  

jl@lillebyfrisch.no  

About BerGenBio ASA  

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.  

Forward looking statements  

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.  

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.